MX2021008453A - Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. - Google Patents
Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.Info
- Publication number
- MX2021008453A MX2021008453A MX2021008453A MX2021008453A MX2021008453A MX 2021008453 A MX2021008453 A MX 2021008453A MX 2021008453 A MX2021008453 A MX 2021008453A MX 2021008453 A MX2021008453 A MX 2021008453A MX 2021008453 A MX2021008453 A MX 2021008453A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- antibodies
- bind human
- antibody
- amenable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente divulgación se refiere, entre otras cosas, a formulaciones estables que comprenden un anticuerpo que se une a CD137 humano o a sus fragmentos de unión a antígeno, y al uso de las formulaciones en métodos para tratar o mejorar diversas enfermedades y afecciones, incluyendo el cáncer, que son susceptibles de tratamiento con un anticuerpo CD137.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962793342P | 2019-01-16 | 2019-01-16 | |
US202062960501P | 2020-01-13 | 2020-01-13 | |
PCT/US2020/013916 WO2020150496A1 (en) | 2019-01-16 | 2020-01-16 | Formulations of antibodies that bind human cd137 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008453A true MX2021008453A (es) | 2021-08-19 |
Family
ID=69724049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008453A MX2021008453A (es) | 2019-01-16 | 2020-01-16 | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220111047A1 (es) |
EP (1) | EP3911679A1 (es) |
JP (1) | JP2022518441A (es) |
KR (1) | KR20210131312A (es) |
CN (1) | CN113474371A (es) |
AU (1) | AU2020208397A1 (es) |
BR (1) | BR112021013571A2 (es) |
CA (1) | CA3127072A1 (es) |
IL (1) | IL284208A (es) |
MX (1) | MX2021008453A (es) |
SG (1) | SG11202107538VA (es) |
WO (1) | WO2020150496A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4294843A1 (en) * | 2021-02-17 | 2023-12-27 | Aptevo Research and Development LLC | Compositions comprising 4-1bb and ox40 binding proteins and methods of use |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
ATE300610T1 (de) | 1994-01-31 | 2005-08-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
AU3117697A (en) | 1996-05-06 | 1997-11-26 | Uab Research Foundation, The | Radiolabeled fusion toxins for cancer therapy |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
WO2011071871A1 (en) * | 2009-12-07 | 2011-06-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for enhancing anti-tumor antibody therapy |
EP3741883B1 (en) | 2010-07-16 | 2022-12-14 | Adimab, LLC | Antibody libraries |
RU2016129959A (ru) | 2013-12-30 | 2018-02-02 | Эпимаб Биотерепьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
CN113214398B (zh) * | 2015-09-22 | 2022-04-08 | 苏州丁孚靶点生物技术有限公司 | 抗人cd137的完全人抗体及其应用 |
EP3652209A2 (en) * | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
WO2019089753A2 (en) * | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
-
2020
- 2020-01-16 CA CA3127072A patent/CA3127072A1/en active Pending
- 2020-01-16 AU AU2020208397A patent/AU2020208397A1/en active Pending
- 2020-01-16 WO PCT/US2020/013916 patent/WO2020150496A1/en unknown
- 2020-01-16 CN CN202080016056.XA patent/CN113474371A/zh active Pending
- 2020-01-16 BR BR112021013571-5A patent/BR112021013571A2/pt unknown
- 2020-01-16 SG SG11202107538VA patent/SG11202107538VA/en unknown
- 2020-01-16 US US17/423,599 patent/US20220111047A1/en active Pending
- 2020-01-16 JP JP2021541095A patent/JP2022518441A/ja active Pending
- 2020-01-16 KR KR1020217022565A patent/KR20210131312A/ko unknown
- 2020-01-16 EP EP20707872.6A patent/EP3911679A1/en active Pending
- 2020-01-16 MX MX2021008453A patent/MX2021008453A/es unknown
-
2021
- 2021-06-20 IL IL284208A patent/IL284208A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022518441A (ja) | 2022-03-15 |
US20220111047A1 (en) | 2022-04-14 |
SG11202107538VA (en) | 2021-08-30 |
AU2020208397A1 (en) | 2021-08-12 |
IL284208A (en) | 2021-08-31 |
CN113474371A (zh) | 2021-10-01 |
EP3911679A1 (en) | 2021-11-24 |
CA3127072A1 (en) | 2020-07-23 |
WO2020150496A1 (en) | 2020-07-23 |
KR20210131312A (ko) | 2021-11-02 |
BR112021013571A2 (pt) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551491A1 (en) | USE OF ANTI-HUMAN SIRPA Vl ANTIBODIES AND METHOD FOR PRODUCING ANTI-SIRPA Vl ANTIBODIES | |
PH12020551865A1 (en) | Anti-msr1 antibodies and methods of use thereof | |
PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
CR20220396A (es) | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
WO2019224716A3 (en) | Antibodies specific for gucy2c and uses thereof | |
MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. | |
MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
MX2021000392A (es) | Anticuerpos anti-mesotelina. | |
IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
GEP20135826B (en) | Novel antibodies used to treat cancer | |
WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
WO2022081718A8 (en) | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof | |
MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
ZA202008095B (en) | Humanized antibodies against psma | |
MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). | |
CR20230245A (es) | Moléculas de unión a gucy2c y sus usos | |
MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
MX2022014995A (es) | Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april. | |
MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
MX2022008745A (es) | Anticuerpos anti-nkp30 y metodos de uso. |